Day: July 20, 2020

Attached herewith the  Bayport Management Ltd Social Bond Letter 2019.AttachmentsBayport Social Bond Investor Letter June 2020Bayport Social Bond Investor Letter June 2020Bayport Social Bond Investor Letter June 2020

TORONTO, July 20, 2020 (GLOBE NEWSWIRE) — ANGUS VENTURES INC. (TSX-V: GUS) (“Angus” or the “Company”) is pleased to announce that it has completed the acquisition of 17 claims in the Mishibishu Greenstone Belt, Ontario (the “Claims”) previously announced in the Company’s July 6, 2020 news release.In consideration for the acquisition of 100% interest in the Claims, the Company paid to the vendor of the Claims (the “Vendor”) $50,000 in cash and issued to Vendor 225,000 common shares of Angus (“Common Shares”). The Vendor will maintain a 2% net smelter return royalty on production from the Claims, 50% of which can be purchased by the Company for $500,000.The Common Shares issued to the Vendor are subject to the statutory four months and a day hold period.About Angus Ventures:Angus Ventures is a Canadian gold exploration company with...

YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, is awarding the Company up to $18.9 million in additional non-dilutive capital to progress its second product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa (P. aeruginosa), in IND-enabling activities toward future Phase 1 clinical trials. This award provides initial funding of $4.9...

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that David Meeker, M.D., the Chairman of Rhythm’s Board of Directors, has been appointed as the President and Chief Executive Officer (CEO) of the company, effective immediately. Dr. Meeker succeeds Hunter Smith, the Company’s Interim President and CEO and Chief Financial Officer (CFO), who will continue in his role as CFO.  “I am delighted to announce David’s appointment as Rhythm’s new CEO,” said Hunter Smith, CFO of Rhythm. “Since he joined our Board in 2015, David has played a key role in shaping the clinical and commercial strategy for setmelanotide and in fostering our collaborative...

WAKEFIELD, Mass., July 20, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin for COVID-19, targeted to commence in Q4 2020.Recently released in vitro data showed Brilacidin exhibited a potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line—reducing viral load by 95 percent and 97 percent at two efficacious concentrations tested, compared to control (DMSO).The new data, using the same assay method, reveal Brilacidin exhibited a similarly potent inhibitory effect against SARS-CoV-2...

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — Applied Materials, Inc. today introduced a new technology that removes a critical bottleneck to continued 2D scaling in foundry-logic nodes.Applied’s new Selective Tungsten process technology gives chipmakers a new way to build transistor contacts, which are the crucial, first level of wiring that connects the transistor to the rest of the wiring in the chip. The selective deposition innovation lowers contact resistance which impedes transistor performance and increases power consumption. With this technology, node scaling of transistors and their contacts can continue to 5nm, 3nm and below, enabling simultaneous advances in chip power, performance and area/cost (PPAC).Scaling ChallengeWhile advances in lithography have helped shrink the transistor contact vias, the traditional...

China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment ofadult patients with advanced GIST who have received prior treatment with 3 or morekinase inhibitors, including imatinibSHANGHAI, China and SAN FRANCISCO and WALTHAM, Mass., July 20, 2020 (GLOBE NEWSWIRE) —  Zai Lab Limited (NASDAQ: ZLAB) and Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib was recently granted full approval by the U.S. Food and Drug Administration (FDA) for the treatment of fourth-line GIST. Ripretinib is also approved...

BOGOTÁ, Colombia, July 20, 2020 (GLOBE NEWSWIRE) — Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (TSXV: MCCN), a leading Colombian and globally integrated cannabis company, is pleased to announce that it has entered into a distribution agreement with Greenstein Capital Ltd. (“Greenstein” or “GC”), a private Maltese company. This agreement, which includes the distribution of a minimum quantity of 1,000 kg of active cannabinoid ingredients per year, will see MCCN products commercialized in Europe. The companies have also agreed on immediate financing to MCCN via a share issuance and participation in a debenture offering more particularly described below. MCCN and GC have also committed to continue ongoing discussions towards a corporate transaction in the future.Distribution AgreementThe distribution agreement...

Toronto, Ontario and Nucla, Colorado, July 20, 2020 (GLOBE NEWSWIRE) — Western Uranium & Vanadium Corp. (CSE:WUC) (OTCQX:WSTRF) (“Western” or ”Company”)Division of Reclamation, Mining and Safety Permit HearingThis hearing on the status of the Sunday Mine Complex permits is now scheduled for July 22, 2020. This Mined Land Reclamation Board (MLRB) meeting was first scheduled to convene in March, but there were multiple continuances due to procedural and COVID-19 delays. A virtual only format will be utilized to comply with the Colorado Open Meetings Law. The Company has made its pre-hearing submission which has been posted to the Colorado Division of Reclamation, Mining and Safety website and the meeting will also be available for viewing on the Division of Natural Resources MLRB YouTube channel.Oil and Gas ActivitiesWestern...

SANTA CRUZ, Calif. and TORONTO, July 20, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual events is pleased to announce that ICSOBA  has chosen InfernoAR for its 38th annual event November 16-18 at a cost of $40,000, with the potential for additional revenue from ScreenAR. The International Committee for Study of Bauxite, Alumina & Aluminium (ICSOBA) unites industry professionals representing major bauxite, alumina and aluminium producing companies, technology suppliers, researchers and consultants from around the world. With the rapid rise in global demand for video and virtual events, the company is experiencing a surge in demand for its InfernoAR video...